SACHI Trial Results: Savolitinib-Osimertinib Combo Improves PFS in MET-Amplified EGFR-Mutated NSCLC
Haleigh BehrmanDr. Shun Lu said savolitinib plus osimertinib offers a potential new chemo-free treatment option for patients after progression on first-line treatment. Read more
IMpower010 Trial Update Highlights Long-Term Benefits of Adjuvant Atezolizumab in Resected NSCLC
Haleigh BehrmanThe updated data and a recently presented exploratory analysis show the benefits varied based on PD-L1 expression, which may be influenced by a variety of genomic alterations. Read more
Tarlatamab Emerges as New Standard of Care in Second-Line SCLC, with Significant Gains in OS, PFS
Joy CurzioDr. Charles M. Rudin, who presented data from the DeLLphi-304 trial at ASCO 2025, noted that patient-reported outcomes also showed improvements in common symptoms, including dyspnea and cough, with fewer toxicities of grade 3 or higher. Read more
A Paradigm Shift: Final 5-Year Overall Survival Results from CheckMate 816 in Resectable NSCLC
Haleigh BehrmanDr. Patrick Forde recently presented milestone data from the trial that confirms the benefit of neoadjuvant-only chemoimmunotherapy for the treatment of resectable lung cancer. Read more
Lurbinectedin and Atezolizumab Combo Demonstrates Survival Benefit in ES-SCLC
Haleigh BehrmanDr. Luis G. Paz-Ares reviewed new IMforte trial results at the 2025 ASCO Annual Meeting. Read more
Early Data Suggest that a 14-Gene Molecular Assay May Help Predict Recurrence Risk in Patients with Early-Stage Non-Squamous NSCLC
Haleigh BehrmanAuthor Dr. David Spigel says these findings may pave the way for more accurate, biomarker-guided decisions for lung cancer treatment after surgery. Read more
Overcoming Resistance Remains a Challenge in Targeting KRAS
Haleigh BehrmanDana-Farber's Dr. Alice Shaw recently explored various combination strategies that show promise in preventing or delaying resistance in this previously undruggable space. Read more
Beamion LUNG-01 Trial Results Support Zongertinib’s Potential as a First-Line Therapy
Haleigh BehrmanDr. John V. Heymach says the latest findings suggest zongertinib may address an unmet need for patients with HER2-mutant NSCLC. Read more
Results From the AENEAS2 Trial Point to a New Frontline Treatment Option for NSCLC
Nathan PettengillResearch team led by Dr. Shun Lu presents aumolertinib with chemotherapy as an additional first-line treatment option during the 2025 AACR Annual Meeting. Read more
A 40-Year Chase in SCLC: Where We’ve Been and Where We’re Going
Haleigh BehrmanPioneer in SCLC research Dr. John D. Minna reflected on four decades of advancements in the field during his keynote address at the 2025 Hot Topics in SCLC. Read more